Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000736587> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2000736587 abstract "Background Because a substantial portion of DCIS is ER negative and overexpresses HER2, therapy targeting this protein is a promising strategy for HER2−overexpressing DCIS. Preclinical studies have shown that trastuzumab (T) boosts the effectiveness of RT in xenograft models and in cell lines with no detrimental effect on irradiated HER2−normal cells. Studies correlating clinical response with molecular markers in T-treated patients show that apoptosis occurs within 1 wk of starting singleagent T, with little effect on proliferation. Shorter duration treatments with this agent require investigation. Adjuvant trials using T during breast irradiation have already provided ample safety evidence. Will T administered during WBI improve lumpectomy + WBI results in women with HER2−positive DCIS? This trial will allow us to better understand the biology of breast cancer and its prevention and will extend the benefits of breast-conserving surgery for women with DCIS. Trial Design : Post lumpectomy for DCIS without evidence of an invasive component, a central review of each patient9s pure DCIS lesion is carried out for HER2 by IHC analysis. If the HER2 is 2+, FISH analysis is done, and patients whose tumors are HER2 3+ or FISH positive can be randomly assigned to receive 2 doses of T 3 wk apart during WBI or to receive WBI alone. Eligibility criteria : Women 18 years or older with an ECOG status of 0 or 1 who have undergone a margin-clear lumpectomy for DCIS and whose tumors are clinically or pathologically node negative are eligible. DCIS must be HER2 positive by central testing. ER and/or PR status must be known before random assignment. Specific aims : The primary aim is to determine if T given concurrently with WBI is more beneficial in preventing IBC recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS compared with WBI alone for HER2−positive DCIS resected by lumpectomy. Secondary aims are to compare the possible benefit of T given during WBI to that of WBI alone in preventing regional or distant recurrence and contralateral invasive or DCIS breast cancer. B-43 will determine if invasive or DCIS DFS, recurrence-free interval, and OS can be improved with the addition of T to WBI. The effects of T on ovarian function in premenopausal women will also be assessed. Statistical methods and accrual : Our design calls for accrual of 2000 patients during a 7.9-year period. As of May 31, 2011, 578 patients have been entered. A definitive analysis of primary endpoints will be performed when 163 ipsilateral breast cancer events occur (7.5 and 8 years after protocol initiation). This number of events affords 80% power to detect a hazard reduction of 36%, from 1.73 ipsilateral breast cancer events per 100 patient-years to 1.11 events per 100 patient-years. The 36% observed reduction in the hazard of IIBCR-SCR-DCIS on the T arm is based on a projection of 40% hazard reduction if the compliance were perfect, with a 10% noncompliance rate. Supported by PHS grants NCI-U10-CA-69651, NCI-U10-CA-12027, and NCI P30-CA-14599 from the US NCI and Genentech, Inc. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT1-02-05." @default.
- W2000736587 created "2016-06-24" @default.
- W2000736587 creator A5009148837 @default.
- W2000736587 creator A5028188876 @default.
- W2000736587 creator A5028301641 @default.
- W2000736587 creator A5035473383 @default.
- W2000736587 creator A5036002285 @default.
- W2000736587 creator A5038183788 @default.
- W2000736587 creator A5039082481 @default.
- W2000736587 creator A5042718217 @default.
- W2000736587 creator A5051850175 @default.
- W2000736587 creator A5055400101 @default.
- W2000736587 creator A5060639499 @default.
- W2000736587 creator A5067136545 @default.
- W2000736587 creator A5069638847 @default.
- W2000736587 creator A5070962077 @default.
- W2000736587 creator A5083635474 @default.
- W2000736587 creator A5084073855 @default.
- W2000736587 creator A5085590393 @default.
- W2000736587 date "2011-12-15" @default.
- W2000736587 modified "2023-09-27" @default.
- W2000736587 title "OT1-02-05: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy to Radiation Therapy (RT) Alone for Women with HER2−Positive DCIS Resected by Lumpectomy: NSABP B-43." @default.
- W2000736587 doi "https://doi.org/10.1158/0008-5472.sabcs11-ot1-02-05" @default.
- W2000736587 hasPublicationYear "2011" @default.
- W2000736587 type Work @default.
- W2000736587 sameAs 2000736587 @default.
- W2000736587 citedByCount "0" @default.
- W2000736587 crossrefType "proceedings-article" @default.
- W2000736587 hasAuthorship W2000736587A5009148837 @default.
- W2000736587 hasAuthorship W2000736587A5028188876 @default.
- W2000736587 hasAuthorship W2000736587A5028301641 @default.
- W2000736587 hasAuthorship W2000736587A5035473383 @default.
- W2000736587 hasAuthorship W2000736587A5036002285 @default.
- W2000736587 hasAuthorship W2000736587A5038183788 @default.
- W2000736587 hasAuthorship W2000736587A5039082481 @default.
- W2000736587 hasAuthorship W2000736587A5042718217 @default.
- W2000736587 hasAuthorship W2000736587A5051850175 @default.
- W2000736587 hasAuthorship W2000736587A5055400101 @default.
- W2000736587 hasAuthorship W2000736587A5060639499 @default.
- W2000736587 hasAuthorship W2000736587A5067136545 @default.
- W2000736587 hasAuthorship W2000736587A5069638847 @default.
- W2000736587 hasAuthorship W2000736587A5070962077 @default.
- W2000736587 hasAuthorship W2000736587A5083635474 @default.
- W2000736587 hasAuthorship W2000736587A5084073855 @default.
- W2000736587 hasAuthorship W2000736587A5085590393 @default.
- W2000736587 hasConcept C121608353 @default.
- W2000736587 hasConcept C126322002 @default.
- W2000736587 hasConcept C143998085 @default.
- W2000736587 hasConcept C2777757722 @default.
- W2000736587 hasConcept C2777863537 @default.
- W2000736587 hasConcept C2777982462 @default.
- W2000736587 hasConcept C2779572924 @default.
- W2000736587 hasConcept C2779786085 @default.
- W2000736587 hasConcept C2781467025 @default.
- W2000736587 hasConcept C509974204 @default.
- W2000736587 hasConcept C530470458 @default.
- W2000736587 hasConcept C535046627 @default.
- W2000736587 hasConcept C71924100 @default.
- W2000736587 hasConceptScore W2000736587C121608353 @default.
- W2000736587 hasConceptScore W2000736587C126322002 @default.
- W2000736587 hasConceptScore W2000736587C143998085 @default.
- W2000736587 hasConceptScore W2000736587C2777757722 @default.
- W2000736587 hasConceptScore W2000736587C2777863537 @default.
- W2000736587 hasConceptScore W2000736587C2777982462 @default.
- W2000736587 hasConceptScore W2000736587C2779572924 @default.
- W2000736587 hasConceptScore W2000736587C2779786085 @default.
- W2000736587 hasConceptScore W2000736587C2781467025 @default.
- W2000736587 hasConceptScore W2000736587C509974204 @default.
- W2000736587 hasConceptScore W2000736587C530470458 @default.
- W2000736587 hasConceptScore W2000736587C535046627 @default.
- W2000736587 hasConceptScore W2000736587C71924100 @default.
- W2000736587 hasLocation W20007365871 @default.
- W2000736587 hasOpenAccess W2000736587 @default.
- W2000736587 hasPrimaryLocation W20007365871 @default.
- W2000736587 hasRelatedWork W13154270 @default.
- W2000736587 hasRelatedWork W13444744 @default.
- W2000736587 hasRelatedWork W13747749 @default.
- W2000736587 hasRelatedWork W16661828 @default.
- W2000736587 hasRelatedWork W16746045 @default.
- W2000736587 hasRelatedWork W16909223 @default.
- W2000736587 hasRelatedWork W1811689 @default.
- W2000736587 hasRelatedWork W4274565 @default.
- W2000736587 hasRelatedWork W4547747 @default.
- W2000736587 hasRelatedWork W7038429 @default.
- W2000736587 isParatext "false" @default.
- W2000736587 isRetracted "false" @default.
- W2000736587 magId "2000736587" @default.
- W2000736587 workType "article" @default.